TP53 and hepatocellular carcinoma: Sorafenib is known to inhibit mitochondrial function.12–16 To uncover the metabolic adaptations associated with this effect, we systematically analyzed the impact of drug treatment on mitochondrial function in our p53−/−; Myc HCC cell model.